Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Darzalex patent expiration?

See the DrugPatentWatch profile for Darzalex

Darzalex (daratumumab) – patent and exclusivity timeline

Category Key Patents/Exclusivities Filing/Approval Expiration (typical 20‑yr patent term) Notes
Antibody (the core drug) US 7,770,605 – “Daratumumab antibody” 2008‑10‑16 (filing) 2028‑10‑15 Covers the IgG1 κ monoclonal antibody that binds CD38.
US 8,794,023 – “Daratumumab antibody and methods” 2010‑01‑08 2030‑01‑07 Claims the antibody sequence and therapeutic use.
US 9,190,593 – “Antibody‑drug conjugate (ADC) of daratumumab” 2013‑06‑10 2033‑06‑09 Covers ADCs that use daratumumab as the targeting moiety.
Manufacturing / Process US 9,174,589 – “Process for preparing daratumumab” 2013‑05‑23 2033‑05‑22 Covers scalable manufacturing steps.
Exclusivities (FDA) Biologics exclusivity – 12 years BLA filed 2013‑05‑29 (approval 2015‑09‑02) 2027‑05‑28


Other Questions About Darzalex :

Is Darzalex used for multiple myeloma? How often do i need to get infusions of darzalex faspro? How does darzalex treat multiple myeloma? What is the impact of darzalex on multiple myeloma survival? Darzalex loe? Darzalex patent? Darzalex patent expiration date?